WTA
DAWN

Washington Trust Advisors’s Day One Biopharmaceuticals DAWN Stock Holding History

Washington Trust Advisors’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-274
Closed -$1.93K – 612
2025
Q3 		$1.93K Sell
274
-68
-20% -$468 ﹤0.01% 663
2025
Q2 		$2.22K Hold
342
– – ﹤0.01% 606
2025
Q1 		$2.71K Hold
342
– – ﹤0.01% 592
2024
Q4 		$4.33K Hold
342
– – ﹤0.01% 584
2024
Q3 		$4.76K Buy
342
+96
+39% +$1.37K ﹤0.01% 580
2024
Q2 		$3.39K Hold
246
– – ﹤0.01% 603
2024
Q1 		$4.06K Hold
246
– – ﹤0.01% 595
2023
Q4 		$3.59K Hold
246
– – ﹤0.01% 606
2023
Q3 		$3.02K Hold
246
– – ﹤0.01% 609
2023
Q2 		$2.94K Buy
246
+83
+51% +$1.08K ﹤0.01% 604
2023
Q1 		$2.18K Hold
163
– – ﹤0.01% 719
2022
Q4 		$3.51K Hold
163
– – ﹤0.01% 656
2022
Q3 		$3K Hold
163
– – ﹤0.01% 790
2022
Q2 		$3K Buy
+163
New +$1.68K ﹤0.01% 818

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Washington Trust Advisors's DAWN Position: Q4 2025 in Review

Washington Trust Advisors sold out of Day One Biopharmaceuticals (DAWN) in Q4 2025, closing a stake of 274 shares — an estimated $1.93K sold.

Washington Trust Advisors first reported a position in DAWN in Q2 2022 and held it in 14 quarters. The position peaked at $4.76K in Q3 2024. 183 funds tracked by Wall St. Rank hold DAWN as of Q4 2025.

  • Washington Trust Advisors reported no remaining Day One Biopharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Washington Trust Advisors sold 274 Day One Biopharmaceuticals shares in Q4 2025, an estimated $1.93K.
  • Washington Trust Advisors first reported a position in Day One Biopharmaceuticals in Q2 2022 and held it in 14 quarters.
  • Washington Trust Advisors's Day One Biopharmaceuticals position peaked at $4.76K in Q3 2024.
  • 183 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q4 2025.

Based on Washington Trust Advisors's 13F filing for Q4 2025, filed 3 Feb 2026.